全文获取类型
收费全文 | 1831篇 |
免费 | 174篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 26篇 |
妇产科学 | 17篇 |
基础医学 | 225篇 |
口腔科学 | 33篇 |
临床医学 | 159篇 |
内科学 | 199篇 |
皮肤病学 | 18篇 |
神经病学 | 104篇 |
特种医学 | 81篇 |
外科学 | 306篇 |
综合类 | 338篇 |
一般理论 | 1篇 |
预防医学 | 134篇 |
眼科学 | 9篇 |
药学 | 132篇 |
2篇 | |
中国医学 | 76篇 |
肿瘤学 | 196篇 |
出版年
2024年 | 7篇 |
2023年 | 7篇 |
2022年 | 34篇 |
2021年 | 42篇 |
2020年 | 33篇 |
2019年 | 18篇 |
2018年 | 25篇 |
2017年 | 33篇 |
2016年 | 22篇 |
2015年 | 78篇 |
2014年 | 62篇 |
2013年 | 97篇 |
2012年 | 126篇 |
2011年 | 139篇 |
2010年 | 116篇 |
2009年 | 101篇 |
2008年 | 90篇 |
2007年 | 90篇 |
2006年 | 90篇 |
2005年 | 105篇 |
2004年 | 57篇 |
2003年 | 60篇 |
2002年 | 75篇 |
2001年 | 40篇 |
2000年 | 52篇 |
1999年 | 44篇 |
1998年 | 31篇 |
1997年 | 30篇 |
1996年 | 30篇 |
1995年 | 30篇 |
1994年 | 15篇 |
1993年 | 32篇 |
1992年 | 24篇 |
1991年 | 13篇 |
1990年 | 14篇 |
1989年 | 18篇 |
1988年 | 24篇 |
1987年 | 19篇 |
1986年 | 22篇 |
1985年 | 13篇 |
1984年 | 11篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1973年 | 5篇 |
排序方式: 共有2065条查询结果,搜索用时 46 毫秒
1.
目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石,共10批。观察绿松石样品和粉末的性状并进行理化鉴别;按2020年版《中国药典》(四部)通则方法测定绿松石样品中水分、浸出物含量;采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物,表面蓝绿色,体重,质硬脆,难砸碎,断面呈贝壳状,蜡样光泽,粉末呈灰绿色,无臭,味淡;理化鉴别结果显示,呈铜盐反应;10批次样品中水分含量为0.41%-3.94%(SD=1.37%),浸出物含量为0.21%-0.81%(SD=0.21%),铜元素含量为3.03%-4.63%(SD=0.63%)。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%,铜元素含量应为2.60%-4.84%,制定的标准可用于蒙药材绿松石的质量控制。 相似文献
2.
3.
目的 观察优克龙 (Urocalun )治疗输尿管结石的疗效和安全性。 方法 对 6 0例输尿管结石直径 <1cm的患者予口服优克龙治疗 ,4 5 0mg/次 ,3次 /d ,服药 5周。 结果 6 0例患者中结石排出 4 5例 (75 % ) ;10例 (17% )结石位置下降 ;5例 (8% )位置无变化。 4例患者服药后有轻度胃部不适、恶心或口干。 结论 优克龙治疗输尿管结石效果良好。 相似文献
4.
Richard J Levy Whitney B Stern Kimberly I Minger Lisa M Montenegro Chitra Ravishankar Jonathan J Rome Susan C Nicolson David R Jobes 《Pediatric critical care medicine》2005,6(6):671-675
BACKGROUND: Mixed venous saturation (S & OV0456;o2) is an important measurement that helps guide the care of critically ill patients. Invasive S & OV0456;o2 assessment in infants and children is often avoided because of the inherent risks. A noninvasive tissue saturation (S to 2) monitor has recently been developed that uses near-infrared spectroscopy to measure oxyhemoglobin saturation in muscle. In adult and animal studies, S to 2 correlated with oxygen delivery and S & OV0456;o2. There has been no evaluation in pediatric patients. OBJECTIVE: To evaluate tissue saturation as a noninvasive measure of mixed venous saturation in children. DESIGN: A prospective observational study. SETTING: Catheterization laboratory in a tertiary care children's medical center. PATIENTS: We studied 98 children (49 without intracardiac mixing and 49 with intracardiac mixing) 相似文献
5.
目的 通过彩色多普勒超声心动图 (CDUCG)和核磁共振成像 (MRI)诊断主动脉夹层动脉瘤 (AD)的影像学特征 ,比较两种无创检查技术诊断AD的临床价值。方法 对临床疑诊AD的患者行CDUCG心脏各切面探查 ,重点扫查并测量主动脉各节段异常超声征象 (夹层发生部位、内膜片跨度、管径宽度等 ) ,对相同患者行MRI检查时在扫描图像上辨认并确定夹层发生的部位、撕裂范围等。结果 CDUCG诊断Ⅰ型AD 4例 ,Ⅱ型 2例 ,Ⅲ型AD 1例。MRI对Ⅰ、Ⅱ、Ⅲ型AD均可明确诊断。本文 3例Ⅲ型AD经MRI确诊并检出附壁血栓 2例 ,1例Ⅰ型AD可疑 ,余结果同CDUCG。结论 两种技术诊断AD各有优缺点 ,CDUCG偏重于诊断Ⅰ、Ⅱ型 ,MRI适合各型AD的诊断。前者更为迅速、直观 ,重复性强 ,可了解心血管病变的全部信息 ;危急重症患者不宜或难以接受MRI检查。 相似文献
6.
Ziprasidone is an atypical antipsychotic with a unique receptor-binding profile. Currently, ziprasidone is approved by the US Food and Drug Administration for the acute treatment of psychosis in schizophrenia and mania in bipolar disorder. When compared to certain other atypical antipsychotics, ziprasidone appears to have a relatively benign side effect profile, especially as regards metabolic effects eg, weight gain, serum lipid elevations and glucose dysregulation. Taken together, these data suggest that ziprasidone may be a first line treatment for patients with bipolar mania. However, ziprasidone is a relatively new medication for which adverse events after long-term use and/or in vulnerable patient populations must be studied. Unstudied areas of particular importance include the efficacy and safety of ziprasidone in the treatment of bipolar depression and relapse prevention of mania as, well as in the subpopulations of pregnant women, the elderly and pediatric patients. The emergence of mania in patients taking ziprasidone is another topic for further study. 相似文献
7.
Bayrak S; Holmdahl R; Travers P; Lauster R; Hesse M; Dolling R; Mitchison NA 《International immunology》1997,9(11):1687-1699
Type II collagen (CII) is of immunological interest because of its
repetitive structure and properties as an autoantigen. The mouse gene has
recently been cloned, thus enabling T cell-defined epitopes to be
identified. Multiple novel epitopes on mouse CII are here detected in the
autoreactive T cell response. The major response is directed to an epitope
with residues 707-721 located on the CB10 fragment. Some 25 other epitopes
are also recognized, including the autologous homologue of the 256-270
epitope which dominates in the response to foreign collagen. The cells
reactive with mouse collagen peptides were of Th1 type, as judged by
release of IFN-gamma. No significant reactivity was detected to mouse CII
peptides during ongoing disease. Alignment of the mouse epitopes revealed a
sequence motif with characteristic side chains at residues P1, P4 and P7,
and to a lesser extent at P5, within a nonamer core sequence. Binding of
these epitopes was simulated in a computer model of the I-Aq molecule,
where peptides with anchor residues at P1, P4 and P7 were indeed found to
fit the binding groove best. The spacing of pockets and the fine structure
of the binding surface of the I-Aq molecule meshes with the repetitive
structure of the collagen (X-Y-Gly), thus providing a likely explanation
for the occurrence of multiple epitopes. Comparison with human DR binding
motifs showed that the I-Aq motif resembles most closely that of the DR4
subtypes which predispose for rheumatoid arthritis.
相似文献
8.
9.
10.
A L Jones T J Powles J G Treleaven J F Burman M C Nicolson H I Chung S E Ashley 《British journal of cancer》1992,66(4):744-747
Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity. 相似文献